As of 6 Nov 2026, Solara Active Pharma Sciences trades at 82.2× trailing earnings, above the industry P/E of 28.7×, and the shares are 18% below their 52-week high. Its ROCE of 4.8% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales fell 1.2% a year over 3 years. Debt is 0.41× equity. It is a small-cap company with a market cap of ₹3,058 Cr, ranked 53rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 4.2% over the past year.
- ₹640.00
- ₹642.80
- ₹623.40
- ₹643.30
- 1.7 L
Health check
- ReturnsBehind
+4.2% over a year, better than 1 of 7 peers.
- Price tagPricier
P/E 82.2 vs industry 28.7.
- GrowthShrinking
Sales −1.2% a year over 3 years.
- ProfitabilityWeak
ROCE 4.8% vs peer median 17.9%.
- Balance sheetStretched
Debt 0.41× equity, interest covered 0.9×, Piotroski 3 of 9.
- Red flags3 to check
Return on equity is low at 2.7%.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹3,058 Cr
- Small cap
- P/E
- 82.2
- Industry 28.7
- Price to book
- 2.12
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 2.7%
- Peers 14.7%
- ROCE
- 4.8%
- Peers 17.9%
- Debt to equity
- 0.41
- Debt ₹591 Cr
- EPS (TTM)
- ₹7.71
- Face value ₹10
- OPM (TTM)
- 14.8%
- Net margin 2.4%
- Sales growth
- +33.1%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 1.99
- EV/EBITDA 15.6
Strengths and risks
Strengths
- Quarterly sales up 33.1% on a year ago.
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Return on equity is low at 2.7%.
- P/E of 82.2 against an industry P/E of 28.7.
- Interest coverage of only 2.4×.
About Solara Active Pharma Sciences
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. It offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory,…
- Headquarters
- Chennai
- Employees
- 1,669
- Sector
- Healthcare
- ISIN
- INE624Z01016
- Website
- solara.co.in
Price range
- Avg volume (3M)
- 5.8 L
- 1-year return
- plus 4.2%
- From 52-week high
- minus 18.1%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| SOLARASolara Active Pharma Sciences | 633.70 | minus 1.49% | 3,058 | 82.2 | 2.12 | 4.8% | 2.7% | 12.0% | −1.2% | – | 0.00% | plus 4.2% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|
| 314 | 349 | 387 | 382 | 417 | |
| 279 | 318 | 330 | 320 | 341 | |
| 34.7 | 30.6 | 57.7 | 62 | 76.8 | |
| 11.1% | 8.8% | 14.9% | 16.2% | 18.4% | |
| 0.5 | 6.8 | 4.7 | 2.7 | 0.5 | |
| 20.8 | 22.5 | 27.6 | 21.6 | 17.8 | |
| 24.5 | 25.6 | 26 | 26.7 | 26.6 | |
| – | −6.8 | 0.9 | – | −4.5 | |
| −10.1 | −17.4 | 9.6 | 16.3 | 28.5 | |
| −10.1 | −17.4 | 9.6 | 16.3 | 28.5 | |
| -2.36 | -3.98 | 2.20 | 3.52 | 5.92 |
Profit & loss
- Sales CAGR 3Y
- −1.2%
- ROE
- 2.7%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1,379 | 1,238 | 1,241 | 1,330 | |
| – | minus 10.2% | +0.2% | +7.1% | |
| 1,235 | 1,333 | 1,031 | 1,143 | |
| 144 | −94.8 | 211 | 188 | |
| 10.5% | −7.7% | 17.0% | 14.1% | |
| 5 | −1.2 | −8.2 | −12.2 | |
| 83.4 | 99.8 | 103 | 76.9 | |
| 111 | 103 | 99.3 | 99.7 | |
| 0.4 | −189 | 0.4 | −6.2 | |
| −44.8 | −488 | 0.5 | −7.4 | |
| 50.4% | −16.1% | – | – | |
| −22.2 | −567 | 0.5 | −7.4 | |
| -5.68 | -148.51 | 0.14 | -1.68 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 36 | 36 | 40.3 | 44.5 | |
| 1,464 | 898 | 1,054 | 1,208 | |
| 1,013 | 1,012 | 796 | 687 | |
| 386 | 406 | 342 | 393 | |
| 2,899 | 2,351 | 2,232 | 2,333 | |
| 1,160 | 1,111 | 1,076 | 1,055 | |
| 240 | 254 | 279 | 204 | |
| 1.7 | 1.7 | 1.7 | 1.6 | |
| 8.7 | 8.4 | 4 | 53.2 | |
| 1,489 | 976 | 871 | 1,019 | |
| 2,899 | 2,351 | 2,232 | 2,333 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 156 | 109 | 213 | 153 | |
| −81.1 | −3.5 | −36.8 | −98.8 | |
| −113 | −106 | −180 | −53.6 | |
| −37.7 | −0.3 | −4.5 | 0.5 | |
| −111 | −41.1 | −39.9 | −52.8 | |
| 44.9 | 67.8 | 173 | 100 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 16.1% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.